Caricamento...
Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events
Nivolumab is a recently approved medication for the treatment of unresectable malignant melanoma. Many immune-related adverse events (irAEs) associated with nivolumab have been reported, such as pneumonitis, hepatitis, dermatitis, and thyroiditis. Prednisolone can effectively treat irAEs. However, i...
Salvato in:
| Pubblicato in: | Case Rep Oncol |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
S. Karger AG
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5422733/ https://ncbi.nlm.nih.gov/pubmed/28512413 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000463379 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|